\-\ Texto\\:\\ \ \(0\)\
\-\ ua\\-large\\ blood\ \(0\)\
\-\ ovoid\\ filling\\ defect\\ right\\ bladder\\ wall\\ with\\ acute\\ angles\\ to\\ the\\ wall\\.\ \(1\)\
\-\ transitional\\ cell\\ carcinoma\ \(13\)\
\-\ epithelial\\ based\\ malignancy\ \(0\)\
\-\ transitional\\ cell\\ carcinoma\ \(13\)\
\-\ squamous\\ cell\\ carcinoma\ \(52\)\
\-\ adenocarcinoma\ \(192\)\
\-\ other\\ neoplasm\ \(9\)\
\-\ leiomyoma\\,fibroma\\,leiomyosarcoma\\,rhabdomyosarcoma\\,\\ lymphoma\\,pheochromocytoma\\,hemangioma\\,leukoplakia\ \(1\)\
\-\ inflammatory\\,\\ infectious\ \(1\)\
\-\ patient\\ presented\\ with\\ intermittent\\ hematuria\\ for\\ several\\ weeks\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ua\\-large\\:\\ 0\\.15465821796432452\ \(0\)\
\-\ \\-leiomyoma\\:\\ 0\\.15465821796432452\ \(0\)\
\-\ leukoplakia\\:\\ 0\\.15465821796432452\ \(0\)\
\-\ \\-adenocarcinoma\\:\\ 0\\.14249774111239566\ \(0\)\
\-\ \\-transitional\\:\\ 0\\.13538431816312962\ \(0\)\
\-\ \\-squamous\\:\\ 0\\.13538431816312962\ \(0\)\
\-\ carcinoma\\:\\ 0\\.12746987736925613\ \(0\)\
\-\ cell\\:\\ 0\\.12148635324113084\ \(0\)\
\-\ angles\\:\\ 0\\.10394994151000585\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.09890288760734302\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.0968365185607398\ \(0\)\
\-\ transitional\\:\\ 0\\.09178946465807698\ \(0\)\
\-\ epithelial\\:\\ 0\\.09130878090039075\ \(0\)\
\-\ wall\\:\\ 0\\.08684768842942969\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.0843541269953338\ \(0\)\
\-\ fibroma\\:\\ 0\\.08342237567403647\ \(0\)\
\-\ ovoid\\:\\ 0\\.08253762385602081\ \(0\)\
\-\ hematuria\\:\\ 0\\.07111130682752179\ \(0\)\
\-\ hemangioma\\:\\ 0\\.06698782719653304\ \(0\)\
\-\ infectious\\:\\ 0\\.06445359416603225\ \(0\)\
\-\ intermittent\\:\\ 0\\.06435129731847447\ \(0\)\
\-\ bladder\\:\\ 0\\.06084931391664963\ \(0\)\
\-\ filling\\:\\ 0\\.060355088004953206\ \(0\)\
\-\ malignancy\\:\\ 0\\.05793139785616694\ \(0\)\
\-\ based\\:\\ 0\\.05717000635556071\ \(0\)\
\-\ defect\\:\\ 0\\.05611837414561274\ \(0\)\
\-\ inflammatory\\:\\ 0\\.051987999020912695\ \(0\)\
\-\ neoplasm\\:\\ 0\\.05105537852477066\ \(0\)\
\-\ several\\:\\ 0\\.04819461115302434\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04284559007700852\ \(0\)\
\-\ weeks\\:\\ 0\\.04254873257721312\ \(0\)\
\-\ blood\\:\\ 0\\.04091949250016315\ \(0\)\
\-\ presented\\:\\ 0\\.04086592342144577\ \(0\)\
\-\ \\,\\:\\ 0\\.037994395160321034\ \(0\)\
\-\ acute\\:\\ 0\\.03701542682642974\ \(0\)\
\-\ other\\:\\ 0\\.03455506225793769\ \(0\)\
\-\ right\\:\\ 0\\.01581810015983187\ \(0\)\
\-\ patient\\:\\ 0\\.015027928612568209\ \(0\)\
\-\ for\\:\\ 0\\.012791371028819562\ \(0\)\
\-\ to\\:\\ 0\\.00749242295514011\ \(0\)\
\-\ with\\:\\ 0\\.0041054096873645515\ \(0\)\
\-\ the\\:\\ 0\\.0024254260474320315\ \(0\)\
\-\ \\.\\:\\ 0\\.0012455977578016235\ \(0\)\
